This cancer type harbours key alterations in TFs of the p53 family (e.g. TP53 and TP73)26–28, developmental and oncogenic TFs (e.g. NFIB and MYC)28–31, along with the expression of key SCLC subtype-defining TFs (e.g. ASCL1, NEUROD1, POU2F3, and YAP1)32. This evidence concerns the gene NEUROD1 and cancer.